Dr. Richard Stubbs, Chief Medical Officer of Momentum Clinical Research, appeared on TVNZ last night in an important segment focused on New Zealanders’ access to new medicines. As part of the discussion, Dr. Stubbs highlighted the role of clinical trials in making innovative treatments accessible and how Momentum Clinical Research’s network is uniquely positioned to support this mission.

The interview comes as New Zealand takes significant steps to improve healthcare access. Paula Bennett, New Zealand’s former Deputy Prime Minister, was recently appointed to lead Pharmac, with a mandate to drive efficiencies that will enhance medicine accessibility for all New Zealanders. In addition, the NZ Ministry of Health is developing a rare disorders strategy aimed at improving treatment options for those with uncommon conditions, allowing New Zealand to adopt international advancements more seamlessly.

During the segment, Momentum Clinical Research was described as a "one-stop solution" for pharmaceutical companies seeking to conduct trials across both New Zealand and Australia. This designation underscores Momentum’s unique advantage: a trans-Tasman network that offers streamlined processes, an expansive patient database, and local expertise to accelerate trial completion and bring access to new medicines to communities across the region.

Dr. Stubbs highlighted Momentum's pivotal role in improving health outcomes by facilitating access to cutting-edge treatments, especially for those with limited options. “We’re working closely with pharma partners to ensure these new therapies reach the people who need them most,” Dr. Stubbs explained. “Our network and resources allow us to bring clinical trials directly to communities, making life-changing treatments accessible to a broader population.”

Momentum’s extensive infrastructure and dedicated team make it an ideal partner for pharmaceutical companies aiming to navigate the complexities of clinical trials in the region. The organisation’s commitment to streamlining the trial process aligns with New Zealand’s growing focus on healthcare accessibility, supporting the government’s vision for an improved health landscape.

Momentum Clinical Research’s approach is especially relevant as New Zealand progresses its rare disorders strategy, which will play a crucial role in bringing the latest advancements to individuals living with rare conditions. With these initiatives in place, New Zealand’s healthcare sector is primed to meet the diverse needs of its population and bring greater equity in treatment access.

Through continued partnerships and a focus on innovation, Momentum Clinical Research stands ready to make a lasting impact on the region’s healthcare.